Valuation: Acrux Limited

Market Cap 62.73L 44.85L 38.44L 35.98L 32.87L 62.1L 43Cr 4.25Cr 1.66Cr 22Cr 1.68Cr 1.65Cr 71Cr P/E 2024
-3.44x
P/E 2025 -0.95x
Enterprise Value 90.45L 64.66L 55.43L 51.88L 47.39L 89.54L 62Cr 6.14Cr 2.39Cr 31Cr 2.43Cr 2.38Cr 102.86Cr EV / Sales 2024
4.09x
EV / Sales 2025 7.81x
Free-Float
78.27%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Acrux Limited

1 day-10.00%
1 week-10.00%
Current month-10.00%
1 month-25.00%
6 months-35.71%
Current year-40.00%
1 week 0.01
Extreme 0.009
0.01
1 month 0.01
Extreme 0.009
0.01
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.009
0.02
3 years 0.01
Extreme 0.009
0.1
5 years 0.01
Extreme 0.009
0.14
10 years 0.01
Extreme 0.009
0.44
Manager TitleAgeSince
Chief Executive Officer - 01/06/2025
Director of Finance/CFO - 21/06/2021
Chief Tech/Sci/R&D Officer - 24/08/2026
Director TitleAgeSince
Chairman 74 01/01/2006
Director/Board Member - 01/10/2013
Director/Board Member 70 01/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
-10.00%-10.00%-35.71%-80.43% 42.27L
+0.40%-1.04%+16.34%+69.97% 4.77TCr
+0.12%+1.50%+51.38%+122.20% 4.03TCr
+0.40%-0.83%-9.73%+16.84% 1.21TCr
-1.45%-2.77%+11.63%+71.04% 1.17TCr
+0.19%+0.58%+30.98%+158.71% 918.98Cr
+3.49%+2.54%+24.70%+43.56% 757.14Cr
-0.16%+0.58%+47.14%-11.83% 723.59Cr
+3.14%+3.12%+23.40%+215.25% 683.65Cr
-3.24%-9.40%-40.05%+18.52% 541.95Cr
Average -0.71%-1.22%+12.01%+62.38% 1.48TCr
Weighted average by Cap. +0.29%-0.65%+24.48%+84.92%

Financials

2024 2025
Net sales 50.91L 36.39L 31.2L 29.2L 26.67L 50.4L 35Cr 3.45Cr 1.34Cr 17Cr 1.37Cr 1.34Cr 58Cr 11.9L 9L 7L 7L 6L 11.78L 8.14Cr 80.71L 31.4L 4.09Cr 31.94L 31.25L 14Cr
Net income -58L -41.46L -35.54L -33.27L -30.39L -57.41L -40Cr -3.93Cr -1.53Cr -20Cr -1.56Cr -1.52Cr -66Cr -59.45L -42.5L -36.43L -34.1L -31.15L -58.85L -41Cr -4.03Cr -1.57Cr -20Cr -1.6Cr -1.56Cr -68Cr
Net Debt 8L 5L 5L 4L 4L 8L 5.19Cr 51.48L 20.02L 2.61Cr 20.37L 19.93L 8.63Cr 27.72L 19.82L 16.99L 15.9L 14.52L 27.44L 19Cr 1.88Cr 73.13L 9.53Cr 74.41L 72.79L 32Cr
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43
Date Price Change Volume
24/26/24 A$0.009000 -10.00% 15,67,387
21/26/21 A$0.0100 0.00% 5,425
20/26/20 A$0.0100 +11.11% 7,37,986
19/26/19 A$0.009000 -10.00% 20,48,103

Annual profits - Rate of surprise